Selexis, a Geneva, Switzerland-based life sciences company, has signed a commercial license agreement that provides ImmuNext, a Lebanon, New Hampshire-based immunotherapy company, with access to research cell banks from the Selexis to advance development of ImmuNext’s anti-CD40 ligand (CD40L) antibody. ImmuNext is developing this antibody for treatment of chronic autoimmune disorders, such as lupus, inflammatory bowel disease, and multiple sclerosis.

CD40L is a therapeutic target in autoimmunity and graft rejection. CD40L is a protein that is primarily expressed on activated T-cells and is a member of the TNF family of molecules.

Source: Selexis